{"url_path":"/sec/igc/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1326205/0001185185-26-001885-index.html","accession_number":"0001185185-26-001885","cik":"0001326205","ticker":"IGC","issuer_name":"IGC Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1326205/0001185185-26-001885-index.html","primary_entity_key":"0001326205","primary_entity_name":"IGC Pharma, Inc."},"word_count":99,"has_tables":true,"body_markdown":"**Item\n1. Legal Proceedings**\n\n \n\nThe\nCompany may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject\nto many uncertainties, and outcomes are not predictable with assurance. There have been no material developments in the legal proceedings\npreviously disclosed in Part I, Item 3, “Legal Proceedings”, of our Annual Report on Transition Form 10-KT for the transition\nperiod ended December 31, 2025, filed with the SEC on March 18, 2026 (the “2025 Form 10-KT”). For a description of our material\npending legal proceedings, please refer to the 2025 Form 10-KT."}